Stephanie M Casillo, Taylor A Gatesman, Akanksha Chilukuri, Srinidhi Varadharajan, Brenden J Johnson, Daniel R David Premkumar, Esther P Jane, Tritan J Plute, Robert F Koncar, Ann-Catherine J Stanton, Carlos A O Biagi-Junior, Callie S Barber, Matthew E Halbert, Brian J Golbourn, Katharine Halligan, Andrea F Cruz, Neveen M Mansi, Allison Cheney, Steven J Mullett, Clinton Van't Land, Jennifer L Perez, Max I Myers, Nishant Agrawal, Joshua J Michel, Yue-Fang Chang, Olena M Vaske, Antony MichaelRaj, Frank S Lieberman, James Felker, Sruti Shiva, Kelsey C Bertrand, Nduka Amankulor, Costas G Hadjipanayis, Kalil G Abdullah, Pascal O Zinn, Robert M Friedlander, Taylor J Abel, Javad Nazarian, Sriram Venneti, Mariella G Filbin, Stacy L Gelhaus, Stephen C Mack, Ian F Pollack, Sameer Agnihotri
Metabolic reprogramming in pediatric diffuse midline glioma is driven by gene expression changes induced by the hallmark histone mutation H3K27M, which results in aberrantly permissive activation of oncogenic signaling pathways. Previous studies of diffuse midline glioma with altered H3K27 (DMG-H3K27a) have shown that the RAS pathway, specifically through its downstream kinase, extracellular-signal-related kinase 5 (ERK5), is critical for tumor growth. Further downstream effectors of ERK5 and their role in DMG-H3K27a metabolic reprogramming have not been explored...
December 18, 2023: Cell Reports